Found: 52
Select item for more details and to access through your institution.
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 729, doi. 10.1007/s10637-010-9561-9
- By:
- Publication type:
- Article
Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept.
- Published in:
- Clinical Drug Investigation, 2019, v. 39, n. 7, p. 595, doi. 10.1007/s40261-019-00790-9
- By:
- Publication type:
- Article
Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.
- Published in:
- Journal of Cancer Research & Therapeutics, 2014, v. 10, n. 4, p. 967, doi. 10.4103/0973-1482.138017
- By:
- Publication type:
- Article
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.645026
- By:
- Publication type:
- Article
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.638482
- By:
- Publication type:
- Article
Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.
- Published in:
- Clinical & Translational Oncology, 2024, v. 26, n. 7, p. 1539, doi. 10.1007/s12094-024-03383-x
- By:
- Publication type:
- Article
Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).
- Published in:
- Clinical & Translational Oncology, 2023, v. 25, n. 9, p. 2647, doi. 10.1007/s12094-023-03215-4
- By:
- Publication type:
- Article
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2‐positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012‐07).
- Published in:
- European Journal of Cancer Care, 2020, v. 29, n. 4, p. 1, doi. 10.1111/ecc.13253
- By:
- Publication type:
- Article
Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer.
- Published in:
- European Journal of Cancer Care, 2019, v. 28, n. 6, p. N.PAG, doi. 10.1111/ecc.13164
- By:
- Publication type:
- Article
Update on adjuvant hormonal treatment of early breast cancer.
- Published in:
- Advances in Therapy, 2011, v. 28, p. 1, doi. 10.1007/s12325-011-0017-1
- By:
- Publication type:
- Article
The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.
- Published in:
- Cancer & Metastasis Reviews, 2010, v. 29, n. 4, p. 751, doi. 10.1007/s10555-010-9261-0
- By:
- Publication type:
- Article
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 206, n. 3, p. 551, doi. 10.1007/s10549-024-07324-8
- By:
- Publication type:
- Article
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 189, n. 3, p. 689, doi. 10.1007/s10549-021-06334-0
- By:
- Publication type:
- Article
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 184, n. 2, p. 469, doi. 10.1007/s10549-020-05866-1
- By:
- Publication type:
- Article
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 184, n. 2, p. 421, doi. 10.1007/s10549-020-05856-3
- By:
- Publication type:
- Article
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2017, v. 163, n. 3, p. 535, doi. 10.1007/s10549-017-4199-3
- By:
- Publication type:
- Article
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 149, n. 1, p. 151, doi. 10.1007/s10549-014-3248-4
- By:
- Publication type:
- Article
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer.
- Published in:
- Ecancermedicalscience, 2019, v. 13, n. 890-910, p. 1, doi. 10.3332/ecancer.2019.891
- By:
- Publication type:
- Article
Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases.
- Published in:
- Ecancermedicalscience, 2016, v. 10, n. 630-650, p. 1, doi. 10.3332/ecancer.2016.632
- By:
- Publication type:
- Article
Gene expression profiles of breast cancer metastasis according to organ site.
- Published in:
- Molecular Oncology, 2022, v. 16, n. 1, p. 69, doi. 10.1002/1878-0261.13021
- By:
- Publication type:
- Article
A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer
- Published in:
- Oncologist, 2019, v. 24, n. 11, p. e1024, doi. 10.1634/theoncologist.2017-0664
- By:
- Publication type:
- Article
Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2.
- Published in:
- Oncologist, 2019, v. 24, n. 7, p. 893, doi. 10.1634/theoncologist.2018-0407
- By:
- Publication type:
- Article
HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1151496
- By:
- Publication type:
- Article
Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.
- Published in:
- Breast Journal, 2022, v. 2022, p. 1, doi. 10.1155/2022/1507881
- By:
- Publication type:
- Article
Safety of eribulin as third‐line chemotherapy in HER2‐negative, advanced breast cancer pre‐treated with taxanes and anthracycline: OnSITE study.
- Published in:
- Breast Journal, 2019, v. 25, n. 2, p. 219, doi. 10.1111/tbj.13199
- By:
- Publication type:
- Article
miR-203 drives breast cancer cell differentiation.
- Published in:
- Breast Cancer Research, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s13058-023-01690-9
- By:
- Publication type:
- Article
The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy.
- Published in:
- PLoS ONE, 2014, v. 9, n. 10, p. 1, doi. 10.1371/journal.pone.0109611
- By:
- Publication type:
- Article
Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes.
- Published in:
- PLoS ONE, 2012, v. 7, n. 8, p. 1, doi. 10.1371/journal.pone.0042494
- By:
- Publication type:
- Article
Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.
- Published in:
- ESC Heart Failure, 2022, v. 9, n. 2, p. 1127, doi. 10.1002/ehf2.13782
- By:
- Publication type:
- Article
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy.
- Published in:
- NPJ Breast Cancer, 2021, v. 7, n. 12/3/2021, p. 1, doi. 10.1038/s41523-021-00218-8
- By:
- Publication type:
- Article
Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.
- Published in:
- Medical Oncology, 2012, v. 29, n. 3, p. 2240, doi. 10.1007/s12032-011-9979-8
- By:
- Publication type:
- Article
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-50056-y
- By:
- Publication type:
- Article
Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
- Published in:
- PLoS ONE, 2017, v. 12, n. 7, p. 1, doi. 10.1371/journal.pone.0180192
- By:
- Publication type:
- Article
Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.
- Published in:
- PLoS ONE, 2017, v. 12, n. 6, p. 1, doi. 10.1371/journal.pone.0178296
- By:
- Publication type:
- Article
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer.
- Published in:
- JNCI Cancer Spectrum, 2024, v. 8, n. 1, p. 1, doi. 10.1093/jncics/pkad107
- By:
- Publication type:
- Article
What is the Best Hormonal Therapy in Postmenopausal Women with Ductal Carcinoma In Situ?
- Published in:
- Cancer & Chemotherapy Reviews, 2015, v. 10, n. 3, p. 77
- By:
- Publication type:
- Article
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
- Published in:
- Breast Cancer Research & Treatment, 2012, v. 132, n. 3, p. 843, doi. 10.1007/s10549-011-1660-6
- By:
- Publication type:
- Article
Shotgun proteomics of archival triple-negative breast cancer samples.
- Published in:
- Proteomics - Clinical Applications, 2013, v. 7, n. 3/4, p. 283, doi. 10.1002/prca.201200048
- By:
- Publication type:
- Article
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
- Published in:
- NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00625-7
- By:
- Publication type:
- Article
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241248336
- By:
- Publication type:
- Article
Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.
- Published in:
- PLoS ONE, 2016, v. 11, n. 5, p. 1, doi. 10.1371/journal.pone.0155840
- By:
- Publication type:
- Article
Behaviour of breast cancer molecular subtypes through tumour progression.
- Published in:
- Clinical & Translational Oncology, 2012, v. 14, n. 6, p. 481, doi. 10.1007/s12094-012-0827-x
- By:
- Publication type:
- Article
SEOM clinical guidelines for the treatment of early breast cancer.
- Published in:
- Clinical & Translational Oncology, 2010, v. 12, n. 11, p. 711, doi. 10.1007/s12094-010-0584-7
- By:
- Publication type:
- Article
Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain.
- Published in:
- Clinical & Translational Oncology, 2006, v. 8, n. 12, p. 896, doi. 10.1007/s12094-006-0153-2
- By:
- Publication type:
- Article
Randomized Study of Cefepime versus Ceftazidime plus Amikacin in Patients with Solid Tumors Treated with High Dose Chemotherapy (HDC) and Peripheral Blood Stem Cell Support (PBSCS) with Febrile Neutropenia.
- Published in:
- Clinical & Translational Oncology, 2006, v. 8, n. 12, p. 889, doi. 10.1007/s12094-006-0152-3
- By:
- Publication type:
- Article
Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features.
- Published in:
- Breast Care, 2020, v. 15, n. 3, p. 208, doi. 10.1159/000508758
- By:
- Publication type:
- Article